Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4532671
Max Phase: Preclinical
Molecular Formula: C28H26FNO4S
Molecular Weight: 491.58
Molecule Type: Unknown
Associated Items:
ID: ALA4532671
Max Phase: Preclinical
Molecular Formula: C28H26FNO4S
Molecular Weight: 491.58
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ccccc1C(=O)c1sc2cc(O)ccc2c1Oc1ccc(OCCN2CC(CF)C2)cc1
Standard InChI: InChI=1S/C28H26FNO4S/c1-18-4-2-3-5-23(18)26(32)28-27(24-11-6-20(31)14-25(24)35-28)34-22-9-7-21(8-10-22)33-13-12-30-16-19(15-29)17-30/h2-11,14,19,31H,12-13,15-17H2,1H3
Standard InChI Key: SYXNLFSRGJWUCI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 491.58 | Molecular Weight (Monoisotopic): 491.1567 | AlogP: 6.22 | #Rotatable Bonds: 9 |
Polar Surface Area: 59.00 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 9.37 | CX Basic pKa: 7.74 | CX LogP: 5.91 | CX LogD: 5.58 |
Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.28 | Np Likeness Score: -0.81 |
1. Lu Y, Gutgesell LM, Xiong R, Zhao J, Li Y, Rosales CI, Hollas M, Shen Z, Gordon-Blake J, Dye K, Wang Y, Lee S, Chen H, He D, Dubrovyskyii O, Zhao H, Huang F, Lasek AW, Tonetti DA, Thatcher GRJ.. (2019) Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer., 62 (24): [PMID:31746603] [10.1021/acs.jmedchem.9b01580] |
2. Cooper L,Schafer A,Li Y,Cheng H,Medegan Fagla B,Shen Z,Nowar R,Dye K,Anantpadma M,Davey RA,Thatcher GRJ,Rong L,Xiong R. (2020) Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors., 63 (19.0): [PMID:32886512] [10.1021/acs.jmedchem.0c01001] |
Source(1):